On July 4, 2022 EXACT Therapeutics AS (‘EXACT-Tx’ or the ‘Company’) reported regarding the issuance of 5,052 new shares in the Company, for the purpose of issuing shares under the Company’s restricted stock unit (RSU) program to its Board members (Press release, Exact Therapeutics, JUL 4, 2022, View Source [SID1234616459]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The share capital increase pertaining to the issuance of the new shares has now been registered with the Norwegian Register of Business Enterprises. The Company’s new registered share capital is NOK 119,988.876 divided into 29,997,219 shares, each with a nominal value of NOK 0.004.

DISCLOSURE REGULATION This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.